Health In Tech, Inc. is a US-listed company in the insurance brokers industry. Its financial year ends in December.
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $33m. The diluted share count is up 6.6% on a year earlier, which dilutes existing holders.
Our model value for Health In Tech is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Health In Tech, Inc.'s trailing-twelve-month revenue grew 23.0% year on year, with a free-cash-flow margin of -19.7%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to 23.0% (-29.3pp vs the prior quarter), the 2nd consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to gaap revenue expected to be recognized in 2026 from pipeline conversion of $3.10m to $8.30m for the 2026; gaap revenue expected to be recognized in 2027 from pipeline conversion of $6.60m to $17.50m for the 2027.
No model value for Health In Tech, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Health In Tech, Inc. as an asset manager, broker or exchange, with every model that fits that kind of business. Cost of equity 7.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.56 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-book vs peers Book value per share times peers' typical (harmonic-mean) price-to-book. | ~$0.1 ~$0.1–$1.3 | Left out: out of range vs price (0.14x) |
| Dividend discount (two-stage) Dividends for five years at the growth the business can fund, then a steady payout and growth. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Health In Tech, Inc. with insurance brokers in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: High.
Next results: November 12, 2026. Analysts expect revenue of $6m and EPS of −$0.04 (range −$0.06 to −$0.03) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.16 | −900% | $32m | −5% |
| Next | −$0.02 | +88% | $54m | +70% |
Next year's EPS estimate has moved −114.0% in 90 days, across 2 analysts.
The consensus EPS forecast for the current fiscal year is +182.3% on 90 days ago. In the last 30 days, 0 analysts raised Health In Tech, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.06 | $0.14 |
| 60 days ago | −$0.06 | $0.14 |
| 30 days ago | −$0.11 | $0.04 |
| 7 days ago | −$0.11 | $0.04 |
| Now | −$0.16 | −$0.02 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.03 | −$0.03 | −14.7% |
| Mar 2026 | −$0.03 | −$0.03 | −12.5% |
| Dec 2025 | −$0.01 | −$0.01 | 0.0% |
| Sept 2025 | $0.01 | $0.01 | 0.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Last 12 months −77.9%
| Part | Then | Now | Effect |
|---|---|---|---|
| Revenue (last 12 months) | $27m | $33m | +23.0% |
| P/S multiple | 5.6x | 1.1x | −80.9% |
| Share count | 56m | 60m | −6.2% |
Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| HIT | −70% | −63% |
| Industry peers (median) | −19% | −1% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| HIT | 67% | 46% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| HIT | −93% | −74% |
| S&P 500 | −19% | −9% |
Worst fall since December 23, 2024: 93% from March 11, 2025 to October 26, 2026. Getting back needed a 1292% gain, and the shares have not yet recovered.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | −1.5% | +0.5% | 0.0% | −12.8% |
| May 13, 2026 | −19.1% | +1.4% | −33.6% | −29.6% |
| March 25, 2026 | −11.5% | −1.2% | −22.0% | −17.0% |
| November 12, 2025 | −27.0% | −1.6% | −35.8% | −50.7% |
| July 21, 2025 | +45.7% | +0.2% | +41.4% | +176.7% |
| April 14, 2025 | 0.0% | +0.7% | −2.9% | +2.1% |
| March 17, 2025 | −16.9% | −0.3% | −21.6% | −14.2% |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY24 Q4 | $19.5M |
| FY25 Q1 | $22.4M |
| FY25 Q2 | $26.7M |
| FY25 Q3 | $30.7M |
| FY25 Q4 | $33.3M |
| FY26 Q1 | $34.1M |
| FY26 Q2 | $32.8M |
Source: SEC EDGAR filings. Retrieved October 29, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY24 Q4 | 8.4% |
| FY25 Q1 | 12.7% |
| FY25 Q2 | 11.4% |
| FY25 Q3 | 5.0% |
| FY25 Q4 | 6.7% |
| FY26 Q1 | -5.5% |
| FY26 Q2 | -19.7% |
| Fiscal year | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|---|
| Income | ||||
| Revenue | 19 | 19 | 33 | 33 |
| Gross profit | 17 | 15 | 21 | 18 |
| Net income | 2 | 1 | 1 | −4 |
| Diluted EPS | — | $0.01 | $0.02 | −$0.07 |
| Growth (year on year) | ||||
| Revenue | — | +1.8% | +71.0% | +23.0% |
| Net income | — | −72.9% | +90.7% | −390.2% |
| Diluted EPS | — | — | +100.0% | −372.2% |
| Margins | ||||
| Gross margin | 88.0% | 79.2% | 62.8% | 53.9% |
| Net margin | 12.9% | 3.4% | 3.8% | −12.0% |
| Cash flow | ||||
| Cash from operations | 2 | 2 | 3 | −5 |
| Stock-based pay | — | 0 | 2 | 2 |
| Balance sheet | ||||
| Cash | 2 | 8 | 8 | 7 |
| Total debt | 2 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −1 | −8 | −8 | −7 |
| Diluted shares | — | 54m | 58m | 60m |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 4,459 | 4,905 | 8,015 | 9,314 | 8,490 | 7,509 | 8,772 | 8,057 |
| Gross profit | 3,479 | 3,797 | 5,355 | 6,310 | 5,144 | 4,129 | 4,509 | 3,922 |
| Net income | 376 | −144 | 499 | 631 | 452 | −303 | −1,588 | −2,511 |
| Diluted EPS | $0.01 | −$0.01 | $0.01 | $0.01 | $0.01 | −$0.01 | −$0.03 | −$0.04 |
| Growth (year on year) | ||||||||
| Revenue | — | — | +56.4% | +86.2% | +90.4% | +53.1% | +9.4% | −13.5% |
| Net income | — | — | — | +86.6% | +20.2% | — | −418.6% | −498.2% |
| Diluted EPS | — | — | — | 0.0% | 0.0% | — | −400.0% | −500.0% |
| Margins | ||||||||
| Gross margin | 78.0% | 77.4% | 66.8% | 67.7% | 60.6% | 55.0% | 51.4% | 48.7% |
| Net margin | 8.4% | −2.9% | 6.2% | 6.8% | 5.3% | −4.0% | −18.1% | −31.2% |
| Cash flow | ||||||||
| Cash from operations | 2,121 | −531 | 527 | 1,481 | 674 | 451 | −3,319 | −2,912 |
| Stock-based pay | — | — | 493 | 708 | 293 | 77 | 367 | 959 |
| Last 12 months unless stated | HIT | XHG | RDZN | EZRA | HUIZ | GSHD | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $33m | $51m | $60m | $11m | $220m | $402m | $1.5bn |
| Revenue growth, last 12 months | 23.0% | 26.5% | 30.5% | −21.4% | 26.8% | 17.7% | 8.7% |
| Revenue growth, 3-year average | — | — | 53.9% | −5.3% | — | 18.4% | 13.8% |
| Revenue growth, latest quarter | −13.5% | — | 49.0% | −31.6% | — | 20.6% | 3.6% |
| Gross margin | 53.9% | 2.2% | 60.7% | — | 30.6% | — | 49.1% |
| Operating margin | — | −197.2% | −21.6% | −75.1% | 0.4% | 23.3% | 9.4% |
| Operating margin, 3-year average | — | — | −100.3% | −78.8% | −14.3% | 18.7% | 4.9% |
| Net margin | −12.0% | −204.9% | −46.9% | −54.3% | 0.3% | 8.8% | 4.4% |
| Cash from operations / revenue | −15.6% | −3.2% | −37.8% | −42.3% | 1.1% | 21.4% | 10.8% |
| Free-cash-flow margin | −19.7% | −3.2% | −42.5% | −42.3% | 0.6% | 19.8% | 9.5% |
| Free-cash-flow margin, 3-year average | — | — | −42.6% | −19.0% | −14.1% | 22.4% | 13.7% |
| Stock pay / revenue | 5.2% | 0.9% | 0.8% | 27.2% | 1.2% | 5.5% | 1.5% |
| Change in share count | 6.6% | >999% | 11.5% | 91.2% | 1.2% | 13.8% | 6.6% |
| Line of business | Revenue | YoY |
|---|---|---|
| SMR | $26.8M | ▲ 169.4% |
| Revenues From Fees | $26.5M | ▲ 106.1% |
| Revenues From Underwriting Modeling ICE | $6.9M | ▲ 3.2% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Health In Tech, Inc.'s 10-K filed March 25, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Whetstone Capital Advisors, LLC | $1.5M | 1.5M | 32.3% | New |
| Mink Brook Asset Management LLC | $1.1M | 1.1M | 24.2% | ▲ 40.5% |
| Vanguard Capital Management LLC | $574,160 | 568K | 12.2% | ▲ 0.5% |
| Heights Capital Management, Inc | $353,771 | 350K | 7.5% | ▼ 6.2% |
| Blackrock, Inc. | $353,091 | 350K | 7.5% | ▲ 22.8% |
| Geode Capital Management, LLC | $222,855 | 221K | 4.7% | ▲ 20.4% |
| Citadel Advisors LLC | $178,680 | 177K | 3.8% | ▲ 382.9% |
| Vanguard Fiduciary Trust Co | $131,787 | 130K | 2.8% | ▲ 75.0% |
| State Street Corp | $63,529 | 63K | 1.3% | 0.0% |
| Northern Trust Corp | $58,236 | 58K | 1.2% | ▲ 59.5% |
| Xtx Topco Ltd | $23,127 | 23K | 0.5% | ▼ 8.0% |
| Two Sigma Securities, LLC | $18,854 | 19K | 0.4% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Health In Tech, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Hasan Zain Syed Chief Growth Officer | October 16, 2026 | Sell pre-set plan | 3,333 | $0.62 | $2,066 |
| Hayes Timothy Director | September 14, 2026 | Sell | 12,000 | $0.89 | $10,680 |
| Hayes Timothy Director | September 11, 2026 | Sell | 12,000 | $0.91 | $10,920 |
| Hasan Zain Syed Chief Growth Officer | September 11, 2026 | Sell pre-set plan | 11,667 | $0.92 | $10,734 |
| Hayes Timothy Director | September 9, 2026 | Sell | 5,730 | $0.93 | $5,329 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
